It’s been quite a year for Akcea Therapeutics (AKCA). After going public in July 2017, the Cambridge, Mass., company almost immediately filed for FDA approval on two drugs for rare diseases.

Volanesorsen, also known as Waylivra, is intended to treat familial chylomicronemia syndrome (FCS), a condition that leads to a buildup of fat in organs. Inotersen, which has the brand name Tegsedi, treats hereditary transthyretin amyloidosis, known as hATTR for short. The condition leads to a buildup of proteins that can cause issues in the nerves and heart. European authorities have already approved inotersen, and the FDA is set to decide on both those drugs before the end of the year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Excellent commentary.
    Hope that both innovative products succeed by
    having a fairly even physician/ patient preference,
    if they can’t be differentiated in any other way.

    CEO should ideally always be diversity neutral;
    just need the best person available to do a job well.

    • Diversities naturally 8 which politician want to lose himself also don’t want to get down money rates if they don’t continue so soon lose all because if somebody take Africa market so and mark its all money come back and that countries so that time is very horrible I think so

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy